Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2023; 15(01): 149-151
DOI: 10.1055/s-0042-1750072
Case Report

Vancomycin-Induced Maturation Arrest with Reactive Promyelocyte Proliferation: A Diagnostic and Therapeutic Challenge

Iffat Jamal 
1   Department of Hematology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
,
Shuchismita Shuchismita
1   Department of Hematology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
,
Vijayanand Choudhary
1   Department of Hematology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Drug-induced leukopenia is a diagnostic and therapeutic challenge. A detailed clinical history is a must to come to a right diagnosis. Certain drugs are known to cause bone marrow suppression, leukopenia, myeloid maturation arrest, and reactive promyelocyte proliferation. Here, we report an unusual case of vancomycin-induced maturation arrest with marked promyelocyte proliferation in a 47-year-old male patient who was being treated for novel coronavirus disease 2019 (COVID-19) infection. Most times, this reactive promyelocyte proliferation is confused with neoplastic promyelocytes, leading to incorrect diagnosis and management.

Keywords

vancomycin - maturation arrest - promyelocyte - proliferation - bone marrow


Publication History

Article published online:
26 July 2022

© 2022. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Arya TV, Prasad RN. Fatal pancytopenia in falciparum malaria. J Assoc Physicians India 1989; 37 (07) 469-470
    PubMedGoogle Scholar
  • 2 Zvulunov A, Tamary H, Gal N. Pancytopenia resulting from hemophagocytosis in malaria. Pediatr Infect Dis J 2002; 21 (11) 1086-1087
    CrossrefPubMedGoogle Scholar
  • 3 Hatton CS, Peto TE, Bunch C. et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; 1 (8478): 411-414
    CrossrefPubMedGoogle Scholar
  • 4 Pipek R, Vulfsons S, Wolfovitz E, Har-Shai Y, Taran A, Peled IJ. Case report: ofloxacin-induced hypersensitivity vasculitis. Am J Med Sci 1996; 311 (02) 82-83
    CrossrefPubMedGoogle Scholar
  • 5 Nepali N, Kalam A, Subish P. et al. Hemoglobinurea due to ofloxacin in a 9 year old child - a case report. Pharmacologyonline 2007; 1: 1-5
    Google Scholar
  • 6 Deng JY, Tovar JM. Pancytopenia with levofloxacin therapy for pelvic inflammatory disease in an otherwise healthy young patient. Ann Pharmacother 2006; 40 (09) 1692-1693
    CrossrefPubMedGoogle Scholar
  • 7 Dutta TK, Badhe BA. Ciprofloxacin-induced bone marrow depression. Postgrad Med J 1999; 75 (887) 571-573
    CrossrefPubMedGoogle Scholar
  • 8 Mitropoulos FA, Angood PB, Rabinovici R. Trovafloxacin-associated leukopenia. Ann Pharmacother 2001; 35 (01) 41-44
    CrossrefPubMedGoogle Scholar
  • 9 Chang CM, Lee NY, Lee HC. et al. Moxifloxacin-associated neutropenia in a cirrhotic elderly woman with lower extremity cellulitis. Ann Pharmacother 2008; 42 (04) 580-583
    CrossrefPubMedGoogle Scholar
  • 10 Naranjo CA, Busto U, Sellers EM. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (02) 239-245
    CrossrefPubMedGoogle Scholar
  • 11 Cunha BA, Quintiliani R, Deglin JM, Izard MW, Nightingale CH. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis 1981; 3 (suppl): S269-S272
    CrossrefPubMedGoogle Scholar
  • 12 Pai MP, Mercier RC, Koster SA. Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy. Ann Pharmacother 2006; 40 (02) 224-228
    CrossrefPubMedGoogle Scholar
  • 13 Dangerfield HG, Hewitt WL, Monzon OT. et al. Clinical use of vancomycin. Antimicrobial Agents Annual 1960; 26-28
    Google Scholar
  • 14 Farber BF, Moellering Jr RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23 (01) 138-141
    CrossrefPubMedGoogle Scholar
  • 15 Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it dose- or duration-related?. Ann Pharmacother 2011; 45 (05) 629-638
    CrossrefPubMedGoogle Scholar
  • 16 Kauffman CA, Severance PJ, Silva Jr J, Huard TK. Neutropenia associated with vancomycin therapy. South Med J 1982; 75 (09) 1131-1133
    CrossrefPubMedGoogle Scholar